stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Return on assets
Zai Lab Limited Unsponsored ADR's return on assets over the twelve months to 30 September 2026 was −18.2%, down 3.3 percentage points from fiscal 2025 (−14.9%). Over the past ten years it has ranged from −73.0% (fiscal 2016) to −14.9% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −14.9% | 8.25 |
| FY2024 | −23.1% | 6.52 |
| FY2023 | −29.7% | 1.67 |
| FY2022 | −31.3% | 17.13 |
| FY2021 | −48.5% | (15.92) |
| FY2020 | −32.5% | 26.83 |
| FY2019 | −59.4% | (8.95) |
| FY2018 | −50.4% | (20.65) |
| FY2017 | −29.8% | 43.18 |
| FY2016 | −73.0% | (37.90) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ADMA ADMA Biologics Inc compare | 28.0% |
| ZLAB Zai Lab Limited Unsponsored ADR | −18.2% |
| XNCR Xencor, Inc. compare | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| MBX MBX Biosciences, Inc. compare | −31.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| RCUS Arcus Biosciences, Inc. compare | −50.6% |
| PHVS Pharvaris N.V. compare | −64.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement